Achilles Therapeutics
London
United Kingdom
About Achilles Therapeutics
Achilles intends to develop next-generation personalized vaccines and adoptive T cell therapies for metastatic cancer by targeting truncal tumor neoantigens. The company is based on research at University College London, Cancer Research UK (CRUK) and the Francis Crick Institute.YEAR FOUNDED:
2016
LEADERSHIP:
Scientific Founder: Charles Swanton
CEO: Chris Ashton
66 articles about Achilles Therapeutics
-
Achilles Therapeutics appoints Dr Markus Dangl as Chief Scientific Officer
2/12/2019
Dr Dangl joins Achilles from Medigene AG where he spent three years as Senior Vice President for Research and Non-clinical Development.
-
Achilles Therapeutics receives CTA approval for Phase I/II Study in Non-Small Cell Lung Cancer
1/21/2019
Achilles Therapeutics (“Achilles””), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical Trial Application (CTA) to conduct a Phase I/II study with its lead product, a tumour-derived T cell therapy targeting clonal neoantigens, in development for the treatment of advanced Non-Small Cell Lung Cancer (NSCLC), has been approved by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA).
-
Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer
12/10/2018
Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer immunotherapies, today announces that it has appointed Dr Edwin Moses as Chairman of its Board of Directors.
-
Achilles To Support A Natural History Study Of C3 Glomerulopathy, A Rare Renal Disorder, Conducted By Experts At Imperial College London
2/28/2017
-
Achilles Starts 2017 With Move To Stevenage Bioscience Catalyst
1/4/2017
-
Syncona, Cancer Research Technology Launch Achilles With $17.5 Million
10/6/2016